GRADE 3B FOLLICULAR LYMPHOMA
Clinical trials for GRADE 3B FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new GRADE 3B FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for GRADE 3B FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough lymphoma: experimental drug AZD4512 enters human trials
Disease control Recruiting nowThis study tests a new drug called AZD4512, alone or with other cancer medicines, in adults with relapsed or refractory B-cell Non-Hodgkin lymphoma (a type of blood cancer). The goal is to find safe doses and check if the drug shrinks tumors. About 91 participants will take part …
Matched conditions: GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
One-Shot gene therapy could simplify cancer treatment
Disease control Recruiting nowThis early-phase trial tests a new injection called IASO207 for people with relapsed or refractory B-cell blood cancers. Unlike current CAR-T therapies that require removing and engineering cells in a lab, IASO207 is designed to create cancer-fighting T cells directly inside the …
Matched conditions: GRADE 3B FOLLICULAR LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New dual-targeting CAR t therapy takes on hard-to-treat lymphoma in phase 3 trial
Disease control Recruiting nowThis phase 3 trial tests a new CAR T-cell therapy called rondecabtagene autoleucel (ronde-cel) that targets two proteins (CD19 and CD20) on lymphoma cells. It is compared to standard CD19-targeting CAR T-cell therapy in 400 patients with relapsed or refractory large B-cell lympho…
Matched conditions: GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE3 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New shot takes on tough blood cancers in small safety trial
Disease control Recruiting nowThis early study is testing an injection called IASO208 in 12 adults with certain types of blood cancer that have returned or not improved with standard treatments. The main goal is to see if the treatment is safe and to find the right dose. Researchers will also look at how well…
Matched conditions: GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug aims to supercharge CAR T-Cells against tough lymphoma
Disease control Recruiting nowThis early-phase trial tests whether adding a drug called NT-I7 after standard CAR T-cell therapy can help the immune cells work better and last longer in people with relapsed or refractory large B-cell lymphoma. About 24 participants will receive NT-I7 after their CAR T treatmen…
Matched conditions: GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Double-targeted cell therapy takes on hard-to-treat lymphomas
Disease control Recruiting nowThis early-phase study tests a new type of immune cell therapy (CAR T cells) that targets two proteins, CD79b and CD19, on lymphoma cells. It is for people with non-Hodgkin lymphoma whose cancer has returned or stopped responding to standard treatments. The main goals are to chec…
Matched conditions: GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug offers hope for lymphoma patients who Can't get transplants
Disease control Recruiting nowThis phase 2 study tests the drug epcoritamab in 30 people with relapsed or refractory large B-cell lymphoma who are not eligible for a stem cell transplant. Epcoritamab is a bispecific antibody that helps the immune system target and kill cancer cells. The main goal is to see ho…
Matched conditions: GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Can booster drugs keep lymphoma in check after CAR t therapy?
Disease control Recruiting nowThis study tests whether adding two targeted drugs (mosunetuzumab and/or polatuzumab vedotin) after standard CAR T-cell therapy can help control lymphoma that has returned or not responded to treatment. About 396 adults with certain types of aggressive B-cell lymphoma will be ran…
Matched conditions: GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New antibody combo aims to boost lymphoma remission
Disease control Recruiting nowThis study tests a new drug called TQB2825, a bispecific antibody that helps immune cells attack lymphoma cells, combined with standard R-CHOP chemotherapy. The trial enrolls 90 adults with untreated or relapsed/refractory diffuse large B-cell lymphoma. Researchers will measure h…
Matched conditions: GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Hope for lymphoma patients: new drug cocktail targets resistant cancer
Disease control Recruiting nowThis study tests whether adding either tazemetostat or zanubrutinib to a standard two-drug therapy (tafasitamab and lenalidomide) can shrink tumors or delay cancer return in people with large B-cell lymphoma that came back or didn't respond to prior treatment. About 227 adults wh…
Matched conditions: GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New strategy targets lingering lymphoma DNA in seniors
Disease control Recruiting nowThis study is for people aged 70 and older with a type of blood cancer called DLBCL. After initial chemotherapy, a blood test checks for leftover cancer DNA. If found, patients receive an extra targeted drug (mosunetuzumab) to try to clear it. The goal is to improve disease contr…
Matched conditions: GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: Danielle Wallace • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New 'Two-Pronged' CAR-T attack shows promise for tough blood cancers
Disease control Recruiting nowThis early-phase trial is testing a new treatment called OriV508 for people with multiple myeloma or non-Hodgkin lymphoma that has come back or stopped responding to other treatments. OriV508 is a type of immunotherapy that uses a virus to deliver instructions to the body to make…
Matched conditions: GRADE 3B FOLLICULAR LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 26, 2026 14:38 UTC
-
Smart scans could spare lymphoma patients from extra chemo
Knowledge-focused Recruiting nowThis study tests whether PET scans and blood tests for tumor DNA can help doctors adjust chemotherapy for people with early-stage diffuse large B-cell lymphoma (DLBCL). About 40 participants will receive standard R-CHOP treatment, and their response will be monitored with imaging…
Matched conditions: GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: University of Rochester • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC